TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30551088

Group type: EXPERIMENTAL
Intervention: Multifidus muscle pain
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trapezius muscle pain
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trapezius and multifidus muscle pain
Number of subjects: 15
Study: 27307495

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 60
Study: 25400471

Group type: EXPERIMENTAL
Intervention: Sodium phosphate tablets (NaP, CLICOLONTM)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Polyethylene glycol solution (PEG)
Number of subjects: 320
Study: 21981286

Group type: EXPERIMENTAL
Intervention: VIAject 7 (VJ7)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Insulin lispro (LIS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: VIAject 25 (VJ25)
Number of subjects: 43
Study: 20445469

Group type: EXPERIMENTAL
Intervention: Plain films
Number of subjects: 19

Group type: COMPARATOR
Intervention: CT images
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Posterior ADI measurement
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Endplate method of angulation measurement
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Various measurements for odontoid fractures
Number of subjects: 19
Study: 18646498

Group type: EXPERIMENTAL
Intervention: Meloxicam pre‐emptively administered
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 50
Study: 16220356

Group type: EXPERIMENTAL
Intervention: Study intervention (not specified)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Spontaneous quitting
Number of subjects: 327
Study: 12370325

Group type: EXPERIMENTAL
Intervention: Photographs provided to participants (Intervention)
Number of subjects: 973

Group type: COMPARATOR
Intervention: No photographs provided (Control)
Number of subjects: 973
Study: 10197673

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia with systemic normothermia (Group 2, n = 108)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia with moderate systemic hypothermia (Group 1, n = 92)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia (Group 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (Group 1)
Number of subjects: 200
Study: 7767539

Group type: COMPARATOR
Intervention: Theophylline withdrawal
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Theophylline-naive patients
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bronchial biopsies
Number of subjects: 27
Study: 1637611

Group type: EXPERIMENTAL
Intervention: i.v. tenoxicam 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6610580

Group type: EXPERIMENTAL
Intervention: Fenbufen (600 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30076843

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Argon plasma coagulation (APC)
Number of subjects: 76
Study: 30266886

Group type: EXPERIMENTAL
Intervention: Venoplasty
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 104
Study: 27695824

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg continuous infusion for 5 days, followed by tapering until day 11)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 380
Study: 23726851

Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 mg a day)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Early pramipexole
Number of subjects: 535

Group type: COMPARATOR
Intervention: Delayed pramipexole
Number of subjects: 535
Study: 21849596

Group type: EXPERIMENTAL
Intervention: 500 mg docosahexaenoic acid (DHA) + 150 mg eicosapentaenoic acid (fish oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 μg 5-methyltetrahydrofolate (5-MTHF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both DHA and 5-MTHF supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher DHA in maternal erythrocytes at delivery
Number of subjects: 0
Study: 19229530

Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa/entacapone (LCE)
Number of subjects: 4

Group type: COMPARATOR
Intervention: levodopa/carbidopa (LC)
Number of subjects: 4
Study: 17926983

Group type: EXPERIMENTAL
Intervention: 4.5% desflurane in 50% N2O
Number of subjects: 72

Group type: COMPARATOR
Intervention: 3% desflurane in 50% N2O
Number of subjects: 72
Study: 15602380

Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 19
Study: 11512111

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg/night
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo 25 mg/night
Number of subjects: 10
Study: 9762492

Group type: EXPERIMENTAL
Intervention: Indirect therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Direct with indirect therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 45
Study: 7846776

Group type: EXPERIMENTAL
Intervention: Intrauterine balloon catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: External cervical obturator
Number of subjects: 40
Study: 2108889

Group type: EXPERIMENTAL
Intervention: 3.75 or 7.5 mg leuprorelin acetate depot given subcutaneously once every 4 weeks
Number of subjects: 81
Study: 7001332

Group type: EXPERIMENTAL
Intervention: Vitamin E therapy (25 mg daily by mouth for the first six weeks of life)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30715083

Group type: EXPERIMENTAL
Intervention: Self-compression
Number of subjects: 549

Group type: COMPARATOR
Intervention: Standard compression
Number of subjects: 549
Study: 28786042

Group type: EXPERIMENTAL
Intervention: Quitting smoking or reducing average cigarette consumption to the mean level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported and clinically verified smoking measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Historic 5 years smoking behavior
Number of subjects: 0
Study: 26059696

Group type: EXPERIMENTAL
Intervention: Chemotherapy compliance reporting
Number of subjects: 115
Study: 23934621

Group type: EXPERIMENTAL
Intervention: GSK1521498 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ethanol 0.5 g/kg body weight
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GSK1521498 20 mg + Ethanol 0.5 g/kg body weight
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study: 21367761

Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate (CS) 800 mg once daily for 6 months
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 18957312

Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 30
Study: 17216272

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy followed by supervised exercise
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supervised exercise alone
Number of subjects: 90
Study: 15126148

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil (Viagra)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11217092

Group type: EXPERIMENTAL
Intervention: Ninjin-to (6.0 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9448590

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and oral cyclophosphamide (CY; 2 mg/kg/day) for 1 yr (group A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids and monthly i.v. CY pulses (0.6 g/m2) for 1 yr (group B)
Number of subjects: 25
Study: 8092768

Group type: EXPERIMENTAL
Intervention: IVF stimulation (without embryo transfer)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone support in unstimulated cycles
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (unstimulated cycles without progesterone)
Number of subjects: 39
Study: 2179848

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 1339
Study: 384188

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus chemotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 58
Study: 31335447

Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 298
Study: 26996268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25758370

Group type: EXPERIMENTAL
Intervention: Zn + Se (ZS; 30 mg Zn as zinc‐gluconate and 200 μg Se as high‐selenium yeast)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Zn + placebo (ZP)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Se + placebo (SP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: placebo + placebo (PP)
Number of subjects: 68
Study: 23628045

Group type: EXPERIMENTAL
Intervention: Combined drug group treated with corticosteroid and anti-helicobacter pylori treatment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Single drug group treated only with corticosteroid
Number of subjects: 92
Study: 21924013

Group type: EXPERIMENTAL
Intervention: SIPPV+VG
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HFOV
Number of subjects: 84

Group type: COMPARATOR
Intervention: IMV
Number of subjects: 84
Study: 18771564

Group type: EXPERIMENTAL
Intervention: Daily supplement of 800 IU vitamin D from 27 weeks until delivery
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Single oral dose of 200,000 IU vitamin D
Number of subjects: 180

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 180
Study: 17098369

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 59
Study: 15054378

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx) 400 mg 3 times a day orally (total 1200 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no Ptx)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx)
Number of subjects: 78
Study: 11432027

Group type: EXPERIMENTAL
Intervention: Interventional studies funded by GPEP
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Randomised trials funded by GPEP
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: General practice research funding
Number of subjects: 248
Study: 9597571

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (2 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (ID-Cy)
Number of subjects: 318

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (4 g/m2), etoposide (600 mg/m2), and G-CSF 6 micrograms/kg/day (HD-Cy)
Number of subjects: 318

Group type: COMPARATOR
Intervention: High-dose cyclophosphamide (HD-Cy)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cyclophosphamide (ID-Cy)
Number of subjects: 318
Study: 8062773

Group type: EXPERIMENTAL
Intervention: Plasma derived HB vaccine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Recombinant HB vaccine
Number of subjects: 174
Study: 2890903

Group type: EXPERIMENTAL
Intervention: GLP-1 7-36 infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 7
Study: 29742960

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice-daily
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 27737393

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation of bilateral femoral quadriceps muscles for 30 minutes during hemodialysis, three times per week, for two months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 23494667

Group type: EXPERIMENTAL
Intervention: Exercise implementation intentions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Social implementation intentions
Number of subjects: 40
Study: 23207889

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity (75% HRR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maximal-intensity intervals (95/50% HRR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate-intensity (50% HRR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 45
Study: 19952807

Group type: EXPERIMENTAL
Intervention: Total physical activity (PA) increase of 100 cpm
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Total physical activity (PA) increase
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) changes
Number of subjects: 38
Study: 18458896

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 24
Study: 16875644

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen/medroxyprogesterone acetate [0.625/2.5 mg]
Number of subjects: 866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study: 12806567

Group type: EXPERIMENTAL
Intervention: TDM group (n = 43)
Number of subjects: 84

Group type: COMPARATOR
Intervention: no-TDM group (n = 41)
Number of subjects: 84
Study: 11018571

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8928704

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 U/kg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 1510005

Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin (0.1 U/kg body weight 4 times a day for 7 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bolus injection of insulin (once, n = 6)
Number of subjects: 46
Study: 6845776

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 30
Study: 29610982

Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 38

Group type: COMPARATOR
Intervention: Duraphat
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both agents (Gluma and Duraphat)
Number of subjects: 38
Study: 29518123

Group type: EXPERIMENTAL
Intervention: Competitive learning tool
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group (non-competitive learning)
Number of subjects: 285
Study: 27310945

Group type: EXPERIMENTAL
Intervention: 4000mL cold saline with 0.5% epinephrine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Normal temperature solution
Number of subjects: 420
Study: 24731120

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 1193
Study: 22776336

Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Open inguinal varicocelectomy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Retroperitoneal varicocelectomy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: All groups (preoperative vs postoperative semen parameters)
Number of subjects: 153
Study: 19671656

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 734

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 734
Study: 17472001

Group type: EXPERIMENTAL
Intervention: Cernilton for 3 months (group 1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cernilton for 3 months + antibacterial treatment for 8 months (group IIa)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard antibiotic treatment for 2 months maximally (group IIb)
Number of subjects: 93
Study: 15642574

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 0
Study: 12086555

Group type: EXPERIMENTAL
Intervention: Anakinra (human recombinant interleukin‐1 receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anakinra plus methotrexate (combination therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9802741

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 90

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 90
Study: 7899379

Group type: EXPERIMENTAL
Intervention: Aspirin 900 mg-metoclopramide 10 mg effervescent association (AAM)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 2677293

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and spironolactone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 873714

Group type: EXPERIMENTAL
Intervention: benserazide
Number of subjects: 32

Group type: COMPARATOR
Intervention: chlorpromazine
Number of subjects: 32
Study: 30958332

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) injection
Number of subjects: 186

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 186
Study: 28751548

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pioglitazone 15-30 mg
Number of subjects: 66
Study: 23949558

Group type: EXPERIMENTAL
Intervention: Patient-centered care
Number of subjects: 506

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 506
Study: 24501857

Group type: EXPERIMENTAL
Intervention: Intervention (n = 62)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (n = 41)
Number of subjects: 103
Study: 19341122

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2) with N-acetylcysteine (NAC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric oxygen therapy (HBO2) without N-acetylcysteine (NAC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO2)
Number of subjects: 50
Study: 17597496

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 28
Study: 15490811

Group type: EXPERIMENTAL
Intervention: letrozole 2.5 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: anastrozole 1 mg
Number of subjects: 72
Study: 11557681

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (1 mg 17beta‐estradiol combined with 0.5 mg norethisterone acetate)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 9786808

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 10 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific antidepressant treatment)
Number of subjects: 51
Study: 7973171

Group type: EXPERIMENTAL
Intervention: Incentives, enablers, medication monitors, and chemotherapeutic regimens allowing direct administration of medication combined with effective patient-physician relationship
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional health education and medication labeling methods
Number of subjects: 0
Study: 3293875

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31580705

Group type: EXPERIMENTAL
Intervention: Shi-style cervical mobilizations (SCM)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Traditional massage (TM)
Number of subjects: 360
Study: 31518645

Group type: EXPERIMENTAL
Intervention: AML-DRG model
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: AML-HCT-CR model
Number of subjects: 1414

Group type: EXPERIMENTAL
Intervention: AML-DRG and AML-HCT-CR models
Number of subjects: 1414
Study: 28371900

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC; 2.4 mg/g nicotine or less) cigarettes
Number of subjects: 717

Group type: COMPARATOR
Intervention: Normal nicotine content (NNC; 15.8 mg/g) cigarettes
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Both VLNC and NNC cigarettes
Number of subjects: 717
Study: 26601156

Group type: EXPERIMENTAL
Intervention: AAV9-IGHMBP2 administration via systemic injection
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: AAV9-IGHMBP2 administration in human SMARD1-induced pluripotent stem cell-derived motor neurons
Number of subjects: 1
Study: 23967638

Group type: COMPARATOR
Intervention: Botox group (local injection of botox type A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupuncture group (matrix needling technique and acupuncture at Fengchi, 'Wuxin points', and local Ashi points)
Number of subjects: 42
Study: 21715011

Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 392

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 392
Study: 19596010

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 mg/d for weight <35 kg; 20 mg/d for weight >35 kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 90
Study: 16705580

Group type: EXPERIMENTAL
Intervention: Oral probiotic Lactobacillus casei subspecies rhamnosus (6 x 10^9 cfu/day) added to human milk
Number of subjects: 80

Group type: COMPARATOR
Intervention: Human milk alone
Number of subjects: 80
Study: 12648735

Group type: EXPERIMENTAL
Intervention: Five-factor model for PANSS
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Seven-factor model for PANSS
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Future studies
Number of subjects: 535
Study: 10685484

Group type: EXPERIMENTAL
Intervention: Cotrel-Dubousset instrumentation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Colorado instrumentation
Number of subjects: 67
Study: 8659761

Group type: EXPERIMENTAL
Intervention: Felodipine infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no felodipine)
Number of subjects: 22
Study: 1531993

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 52

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 52